Gene expression analysis reveals Trem2's role in oxLDL processing in atherosclerosis, indicating that Olfr2 modulation may lower inflammation.
Description Atherosclerosis is a lipid-driven immuno-metabolic and inflammatory disorder characterized by plaque formation in the arterial intima, primarily due to the accumulation of modified low-density lipoproteins (LDL) such as oxidized LDL. After oxLDL exposure macrophages acquire a lipid-loaded “foamy” phenotype characterized by the expression of Trem2, which modulate oxLDL uptake, esterification, and storage. When overwhelmed, foamy macrophages can switch to a proinflammatory state, leading to disease progression. This mechanism is still unknown. Here, we described that Olfr2, whose depletion has been shown to be protective in atherosclerosis, is involved in the proinflammatory switch of foam cells that leads to atherosclerosis progression. We found that the lack of Olfr2 in BMDMs mediates less oxLDL accumulation, significantly reducing the lipid marker (BODIPY) signal compared to WT. Gene expression analysis showed significant upregulation of oxLDL processing genes like Abcg1, Pparg, and Trem2 and downregulation of Srebf1 as well as upregulation of anti-inflammatory gene like Il10 in oxLDL-treated Olfr2 KO BMDMs compared to WT BMDMs. Upregulation of Trem2 in Olfr2 KO BMDMs after oxLDL incubation was confirmed by flow cytometry. Similarly, citral, a known Olfr2 inhibitor, upregulated Trem2 after oxLDL incubation. Delineating Olfr2 and Trem2 pathways interplay might help to identify a potential target to lower the disease burden of atherosclerosis in humans. Funding Sources AHA Career developement Award to MO; Augusta Univesrity Start-Up funds to MO Topic Categories Immune Response Regulation: Cellular Mechanisms (IRC)
No takes yet. Share an insight, caveat, or question.
Ijaz et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: